Juniper Pharmaceuticals Inc (JNP) was Downgraded by Northland Capital to ” Market Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Northland Capital advised their investors in a research report released on Aug 18, 2016.
Juniper Pharmaceuticals Inc closed down -0.02 points or -0.28% at $7.12 with 7,460 shares getting traded on Wednesday. Post opening the session at $7.05, the shares hit an intraday low of $7.05 and an intraday high of $7.12 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Dec 8, 2015, C Ann Merrifield (director) purchased 1,600 shares at $12.14 per share price. According to the SEC, on Nov 20, 2015, Nikin Patel (COO) purchased 5,000 shares at $11.67 per share price. On Nov 19, 2015, James A Geraghty (director) purchased 8,000 shares at $11.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Juniper Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health. Juniper develops pharmaceutical products including CRINONE 8% (progesterone gel) which is marketed by Allergan Inc. in the United States and by Merck KGaA Darmstadt Germany in over 90 countries worldwide. The Company has in-house pharmaceutical development clinical trial manufacturing and analytical capabilities to advance its internal development pipeline including a 10% lidocaine bioadhesive vaginal gel in Phase IIb for gynecologic procedure-related pain and intra-vaginal rings for overactive bladder HRT and prevention of preterm birth while also providing consultative services to its pharmaceutical industry customers. Juniper Pharmaceuticals and Juniper Pharma Services are trademarks of the Company in the United States and European Union. CRINONE is a trademark of Allergan Inc. in the United States.